Spectral Medical and Baxter Extend Partnership for PMX in Septic Shock Treatment
• Spectral Medical and Baxter Healthcare Corporation have extended their exclusive supply and distribution agreement for PMX, a therapy for septic shock, by 10 years post-FDA approval.
• The agreement ensures Baxter remains Spectral's exclusive partner for distributing PMX products in the U.S. and Canada, pending FDA approval, enhancing commercialization prospects.
• Baxter's commitment includes a milestone payment to Spectral following the enrollment of 90 patients in the PMX-focused Tigris Trial, highlighting support for PMX's clinical development.
• The Tigris Trial, a confirmatory study of PMX, is designed as a 2:1 randomized trial of 150 patients using Bayesian statistics to evaluate PMX's efficacy in endotoxic septic shock.
Pharma's Evolution in Social Media: From Listening to Collaboration in Rare Disease Communities
• Social media platforms have transformed from basic forums in the 1990s to sophisticated engagement channels, revolutionizing how pharmaceutical companies interact with rare disease patient communities.
• Lundbeck's Huntington's disease Facebook page demonstrates successful pharma-patient engagement, providing support to 25,000 affected individuals and their caregivers through disease awareness and community building.
• The pharmaceutical industry is transitioning from passive social listening to active collaboration, with companies now utilizing crowdsourcing for clinical trial design and patient support program development.
© Copyright 2025. All Rights Reserved by MedPath